文献速递神经创伤神经重症

抗血小板和抗凝药物是轻度创伤性脑损伤出血的危险因素吗

Are Antiplatelet and Anticoagulants Drugs A Risk Factor for Bleeding in Mild Traumatic Brain Injury?
PubMed 文献 · World Neurosurg · 2017-11-10

本研究连续纳入2773例以轻度创伤性脑损伤为主诉就诊于急诊科的患者,评估其头部CT结果并按抗凝和/或抗血小板用药方案分层。在1608例符合头部CT扫描标准且GCS评分为15分的患者中,517例使用抗血小板药物,213例使用抗凝药物。使用抗血小板药物的患者发生颅内出血的风险显著更高,而抗凝治疗患者的风险与一般人群重叠;第二代药物仅抗血小板药物显示出血风险更高的趋势。

要点

  • GCS评分15分且长期抗凝治疗的患者颅内出血风险似乎不高于非抗凝患者。
  • GCS评分15分且使用抗血小板治疗的患者似乎比一般人群更易发生颅内出血。
  • 第二代抗血小板药物有出血风险更高的趋势。

核心结论

  • GCS评分15分且长期抗凝治疗的患者颅内出血风险似乎不高于非抗凝患者。
  • GCS评分15分且使用抗血小板治疗的患者似乎比一般人群更易发生颅内出血,第二代药物有风险更高的趋势。

研究设计与样本

  • 连续纳入2773例以轻度创伤性脑损伤为主诉就诊于急诊科的患者,评估其头部CT结果并按抗凝和/或抗血小板用药方案分层。
  • 1608例符合头部CT扫描标准且GCS评分为15分;517例使用抗血小板药物,213例使用抗凝药物。

主要发现

  • 使用抗血小板药物的患者发生颅内出血的风险显著更高。
  • 抗凝治疗患者的颅内出血风险与一般人群重叠。
  • 第二代药物仅抗血小板药物显示出血风险更高的趋势。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Facing mild traumatic brain injury, clinicians must decide whether to perform a computed tomography (CT) scan to detect a potential intracranial hemorrhage. Many useful guidelines have been developed for the general population, but there is no general consensus about the best practice to adopt when dealing with patients on antiplatelet or anticoagulation drugs. The relatively recent introduction of new anticoagulants and second-generation antiplatelet drugs poses new challenges in this field. There are no data in the literature about the relative risk of intracranial bleeding in such categories. METHODS: We enrolled 2773 consecutive patients presenting at our emergency department with mild traumatic brain injury as chief complaint and evaluated the results of their head CT scans, stratifying their anticoagulation and/or antiplatelet drug regime. RESULTS: Of these patients, 1608 matched the criteria for head CT scan and had a Glasgow Coma Scale (GCS) score of 15; 517 were on antiplatelet drugs, whereas 213 were on anticoagulants. The risk of developing intracranial bleeding was significantly higher for patients on antiplatelet drugs, whereas the risk of anticoagulated patients overlapped with that of the general population. The trend for second-generation drugs was of higher risk of bleeding only for antiplatelets. CONCLUSIONS: Patients with a GCS score of 15 on long-term anticoagulation therapy seem to be at no higher risk for intracranial hemorrhage than are nonanticoagulated patients. On the contrary, patients with a GCS score of 15 on antiplatelet therapy seem to be more prone to developing intracranial bleeding than are the general population, with a trend to be more at risk when it comes to second-generation drugs.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Uccella L, Zoia C, Bongetta D, et al. Are Antiplatelet and Anticoagulants Drugs A Risk Factor for Bleeding in Mild Traumatic Brain Injury? World Neurosurg. 2017. PMID: 29129761. doi:10.1016/j.wneu.2017.10.173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。